The Science of
Psilocybin and
Beyond

Psilocybin and Alzheimer’s Disease: The Neuroplasticity Hypothesis

BDNF collapses 30–40% in Alzheimer's brains. Psilocybin triggers the largest known BDNF surge. Tau phosphorylation fell ~35% in mouse models. Four mechanisms, one disease — the most unexpected convergence in neurodegeneration research.

The Pineal Gland: Science vs Myth

A pea-sized gland at the geometric center of your brain. Descartes called it the seat of the soul. Strassman called it the DMT factory. Borjigin's lab found DMT-producing enzymes everywhere — not just the pineal. The myth, the data, and the truth in between.

5-MeO-DMT vs Psilocybin: Two Doors to the Same Room

Six hours vs fifteen minutes. Davis (2018) showed 5-MeO-DMT mystical intensity equals high-dose psilocybin. GH001 hit -15.5 MADRS in Phase 2b TRD. The pharmacology, phenomenology, and clinical data on two doors into the same room.

Psilocybin and Nicotine Addiction: How a Single Session Breaks the Hardest Habit

80% quit rate after 2-3 sessions vs 13% for nicotine patches. Johns Hopkins researchers have cracked the neuroscience of tobacco addiction — and it starts with the default mode network.

Psilocybin and Anxiety: The Neuroscience of Dissolving Fear

80% of participants reported sustained anxiety relief after a single psilocybin session. The amygdala quiets, the default mode network resets, and fear patterns built over decades dissolve.

Psilocybin and Cluster Headaches: The Neuroscience of the World's Most Painful Condition

They call them suicide headaches — 10 attacks per day, each rated 10/10 pain. No pharmaceutical reliably stops them. Psilocybin does — even at sub-hallucinogenic doses.

Psilocybin and the Immune System: How Psychedelics Rewrite the Body's Inflammatory Code

Chronic inflammation drives depression, anxiety, neurodegeneration. Psilocybin targets the upstream immune switches — through receptors shared with T cells, macrophages, and microglia.

Psilocybin and Sleep Architecture: The Neuroscience of Deep Sleep Restoration

Insomnia isn't a sleep problem — it's a brain-state problem. Psilocybin targets the upstream driver directly, with 72% showing clinically significant sleep improvement after 2 sessions.

Psilocybin and Chronic Pain: The Neuroscience of Breaking the Pain Cycle

Chronic pain rewires the brain's default mode network in the same way addiction does. Psilocybin may be the first compound that directly targets that architecture.

Psilocybin and Nicotine Addiction: The Neuroscience of Breaking Tobacco Dependence

80% abstinence at 6 months. Johns Hopkins' Matthew Johnson landmark trial rewrites what's possible for smoking cessation.

Microdosing Psilocybin: What the Science Actually Says

Does microdosing psilocybin actually work? The most rigorous science — from TrkB-BDNF neuroplasticity to the Szigeti placebo trial — examined with full honesty.

Psilocybin and Neuroplasticity: How a Single Dose Rewires the Brain

A single psilocybin session triggers a 10% increase in dendritic spine density within 24 hours. The structural brain changes persist for weeks. Here is the neuroscience.

Psilocybin and Eating Disorders: The Neuroscience of Breaking Rigid Patterns

Anorexia has the highest mortality of any psychiatric disorder. New clinical trials show psilocybin disrupts the rigid neural patterns that drive eating disorders.

Psilocybin-Assisted Grief Therapy: Clinical Evidence for Healing Complicated Loss

80% of patients showed lasting reductions in grief and death anxiety. The clinical trial evidence for psilocybin in prolonged grief disorder.

Psilocybin and Grief: The Neuroscience of Healing What Cannot Be Fixed

DMN hyperactivity, prolonged grief disorder, and four mechanisms by which psilocybin may help the brain complete what cannot be fixed.

Cognitive Flexibility and Executive Function Under Psilocybin

How psilocybin rebuilds the prefrontal cortex — REBUS, BDNF, and the 72-hour neuroplasticity window.

Ketamine vs Psilocybin: Two Molecules, Two Paths Out of Depression

Ketamine works in hours. Psilocybin works for months. The complete clinical comparison.

Micro to Macro: The Science of Psilocybin Dosing Protocols

From 0.1g microdoses to 5g hero doses — five distinct tiers, their pharmacokinetics, and the clinical evidence behind the 25mg therapeutic standard that Johns Hopkins and COMPASS converge on.

Psilocybin and Alcohol Use Disorder: What the NEJM Trial Found

Bogenschutz 2022 in the New England Journal of Medicine: 83% reduction in heavy drinking days. Two psilocybin sessions restructured craving circuitry where 12 months of naltrexone failed.